@misc{oai:repo.qst.go.jp:00071357,
 author = {Kamada, Tadashi and Imai, Reiko and Tsujii, Hirohiko and Serizawa, Itsuko and 鎌田 正 and 今井 礼子 and 辻井 博彦 and 芹澤 慈子},
 month = {Jun},
 note = {Background: Carbon ion radiotherapy showed promising clinical outcomes in 57 patients with bone and STS during the phase I study (Kamada, JCO 22 4466-4471, 2002). This phase II study was planned thereafter. 
Methods: From April 2000 to February 2007, 301 lesions of 282 patients with bone and STS not suited for surgical resection were enrolled in this phase II study.  A total dose of 64.0 GyE in 16 fractions over 4 weeks was indicated for 15 lesions, that of 70.4 GyE for 276 and remaining 10 receiving 73.6 GyE. Mean age was 52 yrs, (range 12-85); site of origin was the pelvis in 74%, spine or para-spinous soft tissue in 20%, extremities in 5%: bone primary was in 78% and soft tissue in 22%; pathologic subtype in bone sarcoma was chordoma in 42%, chondrosarcoma in 21%, osteosarcoma in 21%; pathologic subtype in STS was MFH in 23%, MPNST in 21%, synovial sarcoma in 13%. 
Results: The 3- and 5-year overall actuarial survival rates were 68%  (95% Cl, 61%-75%) and 52% (95% C1, 43%-61%), respectively, and the actuarial overall local control rates were 85%  (95% C1, 80%- 90%), and 81% (95'%C1, 74%-88%) at 3 years and 5 years of follow-up, respectively. Overall toxicity was acceptable, with 2% skin/soft tissue late G3/4 toxicity. 
Conclusions: Carbon ion radiotherapy shows a substantial local control in the patients with bone and soft tissue sarcomas not suited for surgical resection with acceptable morbidity., 44th ASCO Annual Meeting},
 title = {Carbon Ion Radiotherapy for Bone and Soft Tissue Sarcomas},
 year = {2008}
}